Methylergonovine Maleate Tablets

1. Product Introduction

Methylergonovine maleate (also called methylergometrine maleate) is an ergot-derived uterotonic used under medical supervision to help manage uterine atony and bleeding following childbirth, as indicated in the locally approved product label. It increases uterine smooth-muscle tone and contractions. Oral tablets are not a substitute for emergency treatment of severe postpartum hemorrhage.

Healthy Life Pharma Pvt. Ltd. is identified as the manufacturer and Healthy Inc as the exporter in the supplied product information. Certification and supply claims require documentary verification.

2. Product Specifications

3. Manufacturing Technology

Because each tablet contains only 125 micrograms of active ingredient, manufacturing requires carefully validated blending and content-uniformity controls. Protection from light and suitable packaging may be important depending on stability studies. Specific low-actinic processing, coating techniques, refrigeration and production equipment are not confirmed by the supplied product information.

4. Quality Assurance

Quality testing should follow the applicable approved IP or USP monograph and product specifications, including identification, assay, content uniformity, dissolution where applicable, related substances and stability. Specific numerical release limits and validated methods must be taken from the applicable monograph or approved dossier rather than assumed.

5. Clinical Pharmacology and Uses

Methylergonovine produces increased uterine tone and contractions through actions on uterine smooth muscle and related receptor pathways. It may be prescribed after delivery to support uterine involution and manage uterine bleeding, depending on local authorization and clinical circumstances. It can also constrict blood vessels and markedly raise blood pressure.

Not for labor induction or use before delivery. Acute major postpartum hemorrhage requires immediate emergency obstetric management.

6. Export and Regulatory Support

Potential B2B support may include product dossiers, certificates of analysis, stability information and export documentation, subject to actual availability and destination-country requirements. WHO-GMP certification, COPP, FSC, registration, export permissions and market authorization should be verified before making commercial claims.

7. Frequently Asked Questions

Q: What strength is supplied?
A: 0.125 mg (125 micrograms) per sugar-coated tablet, in IP and USP-labelled variants.

Q: Can it be used to start labor?
A: No. It must not be used before delivery to induce or augment labor.

Q: Is it safe in high blood pressure?
A: Hypertension and preeclampsia/eclampsia are important contraindications because the medicine can cause dangerous vasoconstriction.

Q: What about breastfeeding?
A: Methylergonovine may affect milk production and expose the infant. Follow the exact product label and clinician guidance; some labels advise avoiding breastfeeding during treatment and for at least 12 hours after the last dose.

8. Dosage and Administration

Oral dosing and duration must be prescribed by an obstetric clinician according to the specific approved 0.125 mg product label. Regimens for other strengths, including 0.2 mg products, should not be transferred to this tablet without checking the local label. Do not self-administer for heavy bleeding or substitute oral therapy for emergency care.

9. Side Effects and Precautions

• Serious hypertension and vasospasm: avoid in patients with hypertension, preeclampsia/eclampsia or other label-listed vascular contraindications.
• Cardiac complications: chest pain, coronary vasospasm, ischemia and stroke are serious potential reactions; seek urgent care for concerning symptoms.
• Other effects: nausea, vomiting, headache, abdominal cramps and dizziness may occur.
• Interactions: strong CYP3A4 inhibitors and other vasoconstrictive medicines can increase the risk of ergot toxicity; check all medicines with a clinician.
• Pregnancy and breastfeeding: do not use before delivery; follow product-specific breastfeeding restrictions.

10. Storage Instructions

Protect from light and moisture and store according to the approved label for the specific IP or USP tablet. Refrigeration and a particular temperature range must not be assumed without validated product stability information.